Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TMI-005 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TMI-005 | DRUG | - |
Inclusion Criteria: * Meet American College of Rheumatology (ACR) criteria for RA * Have active RA * Disease duration of at least 6 months * Disease onset at \> 16 years of age. Exclusion Criteria: * Any prior use of anti-TNF alpha biologics, rituximab, receipt of anti-CD4 or diphtheria interleuk...
Top 20 of 28 competitors
TMI-005 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is in Phase 2 clinical development and has been evaluated in a completed clinical trial involving 390 participants with active rheumatoid arthritis.
TMI-005 is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for rheumatoid arthritis.
TMI-005 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and no active trials are currently listed.
TMI-005 has been studied in one completed Phase 2 clinical trial with the identifier NCT00095342. This trial, titled 'Study Evaluating TMI-005 in Active Rheumatoid Arthritis,' enrolled 390 participants in the United States and Canada.
TMI-005 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for rheumatoid arthritis. The completed clinical trial NCT00095342 evaluated its safety and efficacy, but the drug has not received regulatory approval.